Classes
- ?E0110026A | Faculty of Medicine in Pilsen
- Pulmonary medicineEA0110026 | Faculty of Medicine in Pilsen
- Special Fields of Internal Medicine - pneumologyEA0110026A | Faculty of Medicine in Pilsen
- Possibilities of treatement of pleural disseasesED1P011 | Faculty of Medicine in Pilsen
- Allergies and and airway diseases presented at ERS Annual Congress Amsterdam 2011ED1P101 | Faculty of Medicine in Pilsen
- Parapneumonic fluridothorax, pyothoraxED2P011 | Faculty of Medicine in Pilsen
- Autoimunne Interstitial Lung DiseaseED2P101 | Faculty of Medicine in Pilsen
- HAVEDSZ011 | Faculty of Medicine in Pilsen
- Immunopathology of chronic inflammatory and fibrotic lung and airway diseasesEDSZ101 | Faculty of Medicine in Pilsen
Publications
- EGFR mutations in patients with advanced NSCLC2012 | Faculty of Medicine in Pilsen
- Analysis of advancer NSCLC patients with prolonged progression-free survival after EGFR tyrosine kinase therapy2011 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors2010 | Central Library of Charles University
- Dominance of EGFR and insignificant KRAS mutations in prediction of Tyrosin-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status2009 | Central Library of Charles University
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Central Library of Charles University
- Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC2023 | Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Science
- NUT midline pulmonary carcinoma - molecular profiling of three cases and a literature review of the per-spectives for precision oncology2023 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Přínos tyrosinkinázových inhibitorů EGFR v adjuvantní léčbě karcinomů plic2023 | Faculty of Medicine in Pilsen
- Přínos tyrosinkinázových inhibitorů EGFR v adjuvantní léčbě karcinomu plic2023 | Faculty of Medicine in Pilsen
- Nivolumab + ipilimumab v kombinaci s dvěma cykly chemoterapie u pacientky s karcinomem plic a pleurálním výpotkem2023 | Faculty of Medicine in Pilsen
Loading network view...